Skip to main content

Weight-Loss Drug Zepbound May Work Better in Women Than Men

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 12, 2024.

By Dennis Thompson HealthDay Reporter

THURSDAY, Sept. 12, 2024 -- The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval.

All doses of tirzepatide consistently reduced weight in both women and men, researchers found.

But women lost up to 25% of their initial body weight when treated with tirzepatide, compared with just 19% in men, results showed.

Researchers presented the new analysis Wednesday at the European Association for the Study of Diabetes’ annual meeting in Madrid. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

“This post-hoc analysis underscores the consistent benefits of tirzepatide for women and men. More research is needed to understand the mechanism by which females may experience more weight reduction in these trials,” lead researcher Dr. Luis-Emilio García, an associate vice president at Eli Lilly, said in a meeting news release.

Tirzepatide works by mimicking two types of hormones related to hunger and insulin control, GLP-1 and GIP. Its rival drug, Wegovy, only mimics GLP-1.

This new study pooled all the data from four trials that tested tirzepatide against a placebo in nearly 3,000 women and 1,700 men.

The trials tested the weight-loss drug in obese people with or without type 2 diabetes or other weight-related health problems. Some trials also included a three-month lifestyle intervention intended to help people shed pounds.

Across all trials, people’s odds of reaching weight-reduction targets were significantly higher when they took tirzepatide than when they received a placebo.

Women lost 12% to 28% more weight on tirzepatide than placebo, while men lost 9% to 19% compared to placebo.

The safety profile was similar for men and women, although more women reported nausea and vomiting.

The trials were all funded by Eli Lilly, the maker of Zepbound.

Sources

  • European Association for the Study of Diabetes, news release, Sept. 11, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2024

Read this next

Weight-Loss Pill Saxenda Helps Kids as Young as 6

WEDNESDAY, Sept. 11, 2024 -- The weight-loss drug liraglutide helped obese children lower their BMI and reach a healthier weight, researchers report. The findings, published...

Daily Pill Helps People Lose Weight, Combines GLP-1 With Other Drug

WEDNESDAY, Sept. 11, 2024 -- An experimental weight-loss pill appears to help people quickly shed pounds, a new study says. People who took the drug amycretin lost up to 13% of...

Exercising Can Help You Have Healthier Belly Fat

TUESDAY, Sept. 10, 2024 -- Annoyed that you still have a bit of tummy even though you work out all the time? Exercise actually is helping you develop healthier belly fat tissue...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.